Lidanar en es it fr

Lidanar Brand names, Lidanar Analogs

Lidanar Brand Names Mixture

  • No information avaliable

Lidanar Chemical_Formula


Lidanar RX_link

Lidanar fda sheet

Lidanar msds (material safety sheet)

Lidanar Synthesis Reference

No information avaliable

Lidanar Molecular Weight

386.576 g/mol

Lidanar Melting Point

No information avaliable

Lidanar H2O Solubility

No information avaliable

Lidanar State


Lidanar LogP


Lidanar Dosage Forms

Tablet (10 mg, 25 mg, 50 mg, 100 mg) for oral administration; Ampuls (1 mL) for intramuscular administration; Concentrate for oral administration

Lidanar Indication

Used in the treatment of schizophrenia, organic brain disorders, alcoholism and psychoneuroses.

Lidanar Pharmacology

Mesoridazine, the besylate salt of a metabolite of thioridazine, is a phenothiazine tranquilizer. Pharmacological studies in laboratory animals have established that mesoridazine has a spectrum of pharmacodynamic actions typical of a major tranquilizer. In common with other tranquilizers it inhibits spontaneous motor activity in mice, prolongs thiopental and hexobarbital sleeping time in mice and produces spindles and block of arousal reaction in the EEG of rabbits. It is effective in blocking spinal reflexes in the cut and antagonizes d-amphetamine excitation and toxicity in grouped mice. It shows a moderate adrenergic blocking activity in vitro and in vivo and antagonizes 5-hydroxytryptamine in vivo. Intravenously administered, it lowers the blood pressure of anesthetized dogs. It has a weak antiacetylcholine effect in vitro.

Lidanar Absorption

Well absorbed from the gastrointestinal tract.

Lidanar side effects and Toxicity

Oral LD50 is 560 ± 62.5 mg/kg and 644 ± 48 mg/kg in mouse and rat, respectively. Symptoms of overdose may include emesis, muscle tremors, decreased food intake and death associated with aspiration of oral-gastric contents into the respiratory system.

Lidanar Patient Information

Lidanar Organisms Affected

Humans and other mammals